by Srishti Chaudhari | Dec 12, 2025 | FDA, OTC Drugs, Research/Science/Technology, U.S. Regulatory
The FDA’s recent proposal to add bemotrizinol to the over the counter (OTC) sunscreen monograph marks a pivotal moment for the industry. This announcement represents more than just a new active ingredient; it serves as a proof-of-concept for the modernized...
by Sagarika Sharma | Nov 3, 2025 | Health Canada Updates, Importation of NHPs, Natural Health Products, OTC Drugs
Health Canada has launched a 60-day public consultation on its revised “Draft guidance on preparing and submitting summary reports for marketed drugs and natural health products.” The consultation period opened on October 24, 2025, and will close on December 23, 2025....
by Sagarika Sharma | Oct 28, 2025 | Cosmetics, FDA, OTC Drugs, Our View, Research/Science/Technology, U.S. Regulatory
A new sunscreen ingredient, bemotrizinol, is currently under review by the U.S. Food and Drug Administration (FDA) and could be the first new UV filter to be approved in the United States in decades. The European skincare company DSM-Firmenich has submitted a Time and...
by Sagarika Sharma | Oct 28, 2025 | FDA, OTC Drugs, Our View, U.S. Regulatory
The U.S. Food and Drug Administration (FDA) is encouraging the development of new, reliable alternatives to animal testing for sunscreen products. This comes as the agency continues its work on a proposed order, first issued in September 2021, to update the monograph...
by Sagarika Sharma | Aug 26, 2025 | Canadian Quality Assurance, Canadian Regulatory, Cosmetics, Importation of NHPs, Natural Health Products, OTC Drugs, Our View
One year after amendments to the Competition Act, Competition Bureau Canada has released its final guidelines on civil greenwashing claims, which took effect on June 20, 2025. These guidelines, which apply to foreign businesses operating in Canada, clarify the...
by Sagarika Sharma | Aug 26, 2025 | Canadian Regulatory, Natural Health Products, OTC Drugs
Health Canada has finalized and releases GUI-0080, titled “How to Demonstrate Foreign Building Compliance with Drug Good Manufacturing Practices”. This guidance outlines the expectations and acceptable evidence required to demonstrate that foreign buildings involved...
Recent Comments